- By Myra Ramdenbourg
According to GuruFocus Insider Data, the recent CFO sells were: Vertex Pharmaceuticals Inc. (VRTX) and Johnson & Johnson (JNJ).
Vertex Pharmaceuticals Inc.: EVP, CFO and COO Ian F Smith sold 133,750 shares
On July 21, EVP, CFO & COO Ian F Smith sold 133,750 shares at an average price of $160.98. The price of the stock has decreased by 4.24%. Vertex Pharmaceuticals Inc. has a market cap of $38.39 billion and its shares were traded around $154.15. The company has a P/E ratio of 149.66 and P/S ratio of 18.80.
-
Warning! GuruFocus has detected 3 Warning Sign with VRTX. Click here to check it out.
-
The intrinsic value of VRTX
Vertex announced its first-quarter results with revenue of $714.72 million and gross profit of $667.73 million, while the net income was $247.76 million. The 2016 total revenue was $1.7 billion, a 65% increase from 2015. The 2016 gross profit was $1.49 billion, a 64% increase from the year prior. The 2016 net loss was $112.05 million.
On July 21, CEO and President Jeffrey M Leiden sold 216,624 shares at an average price of $160.96. The price of the stock has decreased by 4.23%. On July 21, EVP GMDA, CMO Jeffrey Chodakewitz sold 46,733 shares at an average price of $160.96. The price of the stock has decreased by 4.23%. On July 21, EVPChief Commercial Officer Stuart A Arbuckle sold 101,875 shares at an average price of $161.5. The price of the stock has decreased by 4.55%.
Johnson & Johnson: Exec VP, Finance; CFO Dominic J Caruso sold 82,591 shares
On July 20, Exec VP, Finance; CFO Dominic J Caruso sold 82,591 shares at an average price of $136.72. The price of the stock has decreased by 3.56%. Johnson & Johnson has a market cap of $355.18 billion and its shares were traded around $131.85. The company has a P/E ratio of 22.27 and P/S ratio of 5.07. The trailing 12-month dividend yield of Johnson & Johnson stocks is 2.46%, while the forward dividend yield is 2.55%. Over the past 10 years, Johnson & Johnson had an annual average earnings growth of 3.90%. GuruFocus rated Johnson & Johnson the business predictability rank of 2.5-star .
Johnson & Johnson announced its second-quarter results with revenue of $17.77 billion and gross profit of $12.38 billion, while the net income was $4.4 billion. The 2016 total revenue was $71.89 billion, a 3% increase from 2015. The 2016 gross profit was $50.21 billion, a 3% increase from the year prior. The 2016 net income was $16.54 billion.
On July 24, Exec VP, Chief Scientific Off Paulus Stoffels sold 102,692 shares at an average price of $133.14. The price of the stock has decreased by 0.97%.